Published in J Urol on December 01, 2000
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res (2010) 1.74
Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci (2008) 1.24
MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol (2008) 1.16
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch (2004) 1.00
Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer (2005) 0.99
Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer (2010) 0.94
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer (2008) 0.90
The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol (2012) 0.84
Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett (2013) 0.83
Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays. Hum Pathol (2011) 0.82
Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res (2009) 0.79
Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer (2011) 0.78
Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. World J Urol (2014) 0.78
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget (2015) 0.78
Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression. Am J Transl Res (2010) 0.77
p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process. BMC Cancer (2010) 0.75
Microscopic haematuria. BMJ (1994) 3.00
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. Hum Pathol (1999) 2.06
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res (2001) 1.86
Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol (1993) 1.82
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Future prospects in prostate cancer. Prostate (1999) 1.53
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology (2006) 1.51
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (2003) 1.46
Sperm DNA integrity in cancer patients before and after cytotoxic treatment. Hum Reprod (2010) 1.45
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
Detection of prostate cancer. BMJ (1995) 1.30
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab (2001) 1.22
Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem (1991) 1.20
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol (1997) 1.16
Detection of factor VIII/coagulant antigen in human liver tissue. Nature (1983) 1.16
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res (1990) 1.14
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med (2000) 1.11
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol (1998) 1.10
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry (1992) 1.08
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol (1996) 1.07
Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen (1996) 1.06
Hormonal manipulation of prostatic cancer. BMJ (1991) 1.06
Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet (2000) 1.04
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate (1999) 1.04
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review. Urol Res (1989) 1.04
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol (1998) 1.04
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol (1995) 1.03
An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol (1993) 1.03
Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo. Am J Pathol (1994) 1.02
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int (1995) 1.01
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Screening for prostate cancer. Eur J Cancer (2005) 1.01
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol (1998) 0.99
Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer (2001) 0.98
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol (1990) 0.98
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int (2004) 0.98
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate (2008) 0.97
Localization of factor VIII-procoagulant antigen: an immunohistological survey of the human body using monoclonal antibodies. Blood (1986) 0.97
Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations. Lancet (1985) 0.97
Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene (1988) 0.97
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol (2002) 0.97
Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol (2005) 0.97
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate (1993) 0.97
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol (1994) 0.96
Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene (1991) 0.96
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol (1991) 0.96
Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry (1993) 0.96
Screening for prostate cancer: evidence and perspectives. BJU Int (2001) 0.96
Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int (2002) 0.96
Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer (1999) 0.95